Mevalonates restore zoledronic acid-induced osteoclastogenesis inhibition

Area of Science:

• Biochemistry
• Bone Biology
• Pharmacology

Background:

• Bisphosphonate-related osteonecrosis of the jaw (BRONJ) results from impaired bone healing due to nitrogen-containing bisphosphonates (NBPs).
• NBPs inhibit osteoclast function by disrupting the mevalonic acid pathway.
• This disruption affects osteoclastogenesis and bone remodeling.

Purpose of the Study:

• To investigate if mevalonic acid metabolites can counteract the effects of NBPs on bone healing.
• To examine the specific roles of geranylgeranyl pyrophosphate (GGPP) and geranylgeranyl acid (GGOH) in this process.

Main Methods:

• In vitro studies using mouse osteoclast precursors treated with zoledronic acid (an NBP) and mevalonic acid metabolites (GGOH, GGPP).
• Assessed osteoclast differentiation, multinucleation, and expression of related genes (TRAP, cathepsin K, etc.).
• In vivo studies in mice with zoledronic acid-induced BRONJ-like lesions, evaluating the effects of GGOH and GGPP on bone mineral deposition.

Main Results:

• Zoledronic acid inhibited osteoclast differentiation, multinucleation, and key gene expression.
• GGOH and GGPP treatment restored the number of TRAP-positive multinuclear cells and gene expression inhibited by zoledronic acid.
• In vivo, GGOH and GGPP partially restored bone mineral deposition in zoledronic acid-induced BRONJ-like lesions.

Conclusions:

• Mevalonic acid metabolites (GGOH, GGPP) show potential to reverse NBP-induced inhibition of osteoclastogenesis and bone remodeling.
• These metabolites may serve as therapeutic agents for treating bisphosphonate-related osteonecrosis of the jaw.